Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Blood
|
October 2, 2024
How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
Danielle S Wallace, Kah Poh Loh, Carla Casulo
International Journal of Surgical Pathology
|
July 4, 2025
Clinicopathologic Findings in T-Cell Large Granular Lymphocytic Leukemia-Associated Gamma Heavy Chain Disease
Giby V George, Danielle S Wallace, Chauncey R Syposs
Ejhaem
|
June 19, 2024
Clonally unrelated primary large B-cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune-privileged sites?
Giby V George, Diana G Aldowitz, Audrey N Jajosky, et al.
Blood Advances
|
January 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
Danielle S Wallace, Clive S Zent, Andrea M Baran, et al.
Journal of Adolescent and Young Adult Oncology
|
September 3, 2025
Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort Study
John Mariano, Myla Strawderman, Eric Snyder, et al.
Journal of Geriatric Oncology
|
March 7, 2026
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty
Patrick M Reagan, Allison Magnuson, Craig A Portell, et al.
Leukemia & Lymphoma
|
March 17, 2020
Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
Philip J Meacham, AnnaLynn M Williams, Myla Strawderman, et al.
Leukemia Research
|
April 1, 2023
Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions
Jeremiah E Moore, Paige C Bloom, Charles C Chu, et al.
Blood Advances
|
October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Brian T Hill, Shuo Ma, Clive S Zent, et al.
Blood Advances
|
February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study
Jia Ruan, Zhengming Chen, Melissa C Larson, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Blood
|
October 2, 2024
How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
Danielle S Wallace, Kah Poh Loh, Carla Casulo
International Journal of Surgical Pathology
|
July 4, 2025
Clinicopathologic Findings in T-Cell Large Granular Lymphocytic Leukemia-Associated Gamma Heavy Chain Disease
Giby V George, Danielle S Wallace, Chauncey R Syposs
Ejhaem
|
June 19, 2024
Clonally unrelated primary large B-cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune-privileged sites?
Giby V George, Diana G Aldowitz, Audrey N Jajosky, et al.
Blood Advances
|
January 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
Danielle S Wallace, Clive S Zent, Andrea M Baran, et al.
Journal of Adolescent and Young Adult Oncology
|
September 3, 2025
Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort Study
John Mariano, Myla Strawderman, Eric Snyder, et al.
Journal of Geriatric Oncology
|
March 7, 2026
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty
Patrick M Reagan, Allison Magnuson, Craig A Portell, et al.
Leukemia & Lymphoma
|
March 17, 2020
Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
Philip J Meacham, AnnaLynn M Williams, Myla Strawderman, et al.
Leukemia Research
|
April 1, 2023
Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions
Jeremiah E Moore, Paige C Bloom, Charles C Chu, et al.
Blood Advances
|
October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Brian T Hill, Shuo Ma, Clive S Zent, et al.
Blood Advances
|
February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study
Jia Ruan, Zhengming Chen, Melissa C Larson, et al.
Page
of 2